NasdaqGM:IOVABiotechs
Is Real‑World Amtagvi Response Data Altering The Investment Case For Iovance Biotherapeutics (IOVA)?
In early February 2026, Iovance Biotherapeutics reported real-world retrospective data showing a best-in-class clinical profile and unprecedented response rates for its commercial T cell therapy Amtagvi (lifileucel) in patients with advanced, unresectable or metastatic melanoma.
This real-world evidence suggests Amtagvi could play a more central role in the treatment landscape for previously treated advanced melanoma, potentially reinforcing physician confidence in TIL-based therapies.
We’ll...